Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
dolutegravir
- Development stage
- Approved
- Lead developer
- ViiV Healthcare
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Dolutegravir is an antiretroviral medication used in combination with other drugs to treat human immunodeficiency virus (HIV) infection in adults and children at least 4 weeks old and weighing at least 3 kg. It belongs to the class of HIV integrase strand transfer inhibitors (INSTIs). Dolutegravir works by binding to the active site of HIV integrase and blocking the strand transfer step necessary for viral DNA integration into the host genome, thereby inhibiting viral replication. It is not a cure for HIV/AIDS but helps reduce viral load, increase immune cell counts, and lower the risk of developing AIDS or related illnesses. Dolutegravir has a high barrier to resistance and can be used both in treatment-naive patients and those switching regimens due to resistance or side effects[1][2][3][4][5][6].
- Brand names
- TivicayTivicay PD
- Other names
- dolutegravir
02
Targets
Integrase allosteric pocket (HIV)
Beyond the preview
Go deeper on dolutegravir.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on dolutegravir.